No Data
Novartis Says FDA Gives Accelerated Approval for Kidney-Disease Treatment
Top Gap Ups and Downs on Thursday: LLY, PH, MCK and More
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Novartis Receives FDA Accelerated Approval for Fabhalta (Iptacopan), the First and Only Complement Inhibitor for the Reduction of Proteinuria in Primary IgA Nephropathy (IgAN)
Express News | US FDA Approves Novartis' Fabhalta For Reducing Proteinuria In Adults With Primary Immunoglobulin A Nephropathy (IgAN)
New Drugs and Cost Controls Fuel Wave of Pharma Guidance Lifts -- Analysis
No Data
